Visionary Holdings (Nasdaq: GV) Establishes Three Wholly Owned Subsidiaries in Qingdao, Wuxi and Wuhu, Advancing Commercial Expansion in China
MWN-AI** Summary
Visionary Holdings Inc. (Nasdaq: GV) has announced the establishment of three wholly owned subsidiaries in Qingdao, Wuxi, and Wuhu, China, marking a significant step in its efforts to expand its commercial presence in the region. This initiative aligns with the company's strategy to enhance localized market engagement and sales capabilities for its portfolio in regenerative medicine, cellular rejuvenation, and aesthetic treatments.
The new subsidiaries will serve as key components in GV's multi-city commercialization network, complementing its existing operations in Hangzhou and Nanjing. Each subsidiary will be strategically positioned: Qingdao in the Shandong Peninsula, Wuxi in the Yangtze River Delta biomedical corridor, and Wuhu in the Anhui regional healthcare market. This aligned approach aims to leverage the healthcare demand and institutional resources of these key areas, enabling GV to effectively deploy its innovative product offerings.
The subsidiaries will focus on several core functions, including the recruitment of sales professionals, cultivating partnerships with regional medical providers, and facilitating the introduction of GV's advanced treatments. This multi-city execution model is designed to enhance revenue visibility through structured sales pipelines while increasing operational transparency.
Xiyong Hou, CEO of Visionary Holdings, expressed that this development signifies a crucial advancement in the company's commercialization journey, emphasizing the shift from strategic planning to execution at a city level. GV's multi-city approach not only strengthens scalability but also positions the company to capitalize on the growing demand for regenerative medicine in Asia.
With a comprehensive operational infrastructure now in place, GV aims to enhance its commercial scalability, institutional penetration, and revenue pathways, supporting its long-term growth strategy in the evolving healthcare landscape.
MWN-AI** Analysis
Visionary Holdings Inc. (Nasdaq: GV) is making significant strides in its commercial expansion strategy, particularly in the fast-growing Asian market. The recent establishment of three wholly owned subsidiaries in Qingdao, Wuxi, and Wuhu positions the company to leverage localized sales execution, institutional partnerships, and enhanced revenue visibility within the rapidly evolving regenerative medicine sector.
This strategic move aligns with GV's goal of transitioning from a technology-driven platform to a cohesive sales operation across multiple cities. The regional focus on key markets—like the Shandong Peninsula and the Yangtze River Delta—indicates a calculated approach to capitalize on diversified healthcare demands and institutional resources, making it a strong contender in the growing aesthetic and regenerative medicine markets.
From an investment perspective, GV's phased strategic roadmap showcases an impressive track record, including global technology licensing and a robust product portfolio that demonstrates significant growth potential. The ongoing recruitment of professional sales teams and partnerships with local medical providers are expected to boost market penetration, providing a clearer visibility on revenue pathways.
Given the explosive growth anticipated in China’s healthcare sector, investors should view GV's expansion as a solid long-term opportunity. However, they should remain cautious of inherent risks indicated in the company's forward-looking statements regarding market volatility and regulatory challenges.
For investors looking for growth in the healthcare tech space, GV’s structured commercialization approach, combined with a robust operational infrastructure across key Chinese markets, suggests a positive trajectory. It may be prudent for investors to consider both the current valuation and the potential for scalability as GV continues to establish itself as a leader in technological healthcare solutions. Overall, cautiously optimistic investment strategies may well serve those looking to capitalize on GV's growth story.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
HONG KONG, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (“GV” or the “Company”) (Nasdaq: GV), a technology-driven multinational enterprise, today announced that its wholly owned subsidiary, Visionary Health Technology Group Limited, has established three new regional wholly owned subsidiaries in Qingdao, Wuxi and Wuhu, China.
These subsidiaries are primarily dedicated to localized market expansion, institutional partnerships, and frontline sales execution for GV’s regenerative medicine, cellular rejuvenation, and aesthetic treatment product portfolio.
This development represents a meaningful operational milestone in GV’s transition from strategic platform buildout to coordinated multi-city commercial execution.
Building a Multi-City Commercial Network
Following the launch of GV’s Asia Headquarters in Hangzhou and the establishment of its sales entity in Nanjing, the addition of Qingdao, Wuxi and Wuhu forms a structured regional commercialization matrix covering:
• Shandong Peninsula (Qingdao)
• Yangtze River Delta biomedical corridor (Wuxi)
• Anhui regional healthcare market (Wuhu)
Together, these cities provide diversified healthcare demand bases, strong institutional resources, and access to premium consumer markets.
Core Functions of the Three Subsidiaries
Each regional subsidiary will focus on:
Localized Sales Execution
Recruiting and building professional sales teams to directly support hospitals, aesthetic clinics, and premium wellness institutions.
Institutional Partnerships
Developing strategic cooperation with regional medical providers, healthcare platforms, and channel partners.
Product Deployment and Market Onboarding
Supporting rollout of GV’s stem-cell-based rejuvenation programs, NK cell revitalization therapies, AI-assisted aging assessment systems, and personalized longevity solutions.
Revenue Visibility Enhancement
Establishing structured sales pipelines and standardized commercialization processes to improve revenue visibility and operational transparency.
A Visible Step Forward in Commercialization
Over the past year, GV has executed a phased strategic roadmap:
• Secured global technology licensing in regenerative medicine
• Launched stem cell–based anti-aging product portfolio
• Established Asia-Pacific operational headquarters
• Built frontline sales infrastructure
• Expanded into multiple regional commercialization hubs
The simultaneous establishment of three additional wholly owned subsidiaries reflects continued progress in translating technology assets into structured sales operations.
Management Commentary
Xiyong Hou, Chief Executive Officer of Visionary Holdings, commented:
“The establishment of wholly owned subsidiaries in Qingdao, Wuxi and Wuhu marks an important step in GV’s commercialization journey. We are progressing from strategic positioning to coordinated city-level execution.
By building localized teams and strengthening regional partnerships, we aim to enhance sales capability and operational visibility. Commercialization is a gradual process, but this multi-city deployment strengthens our scalability and long-term growth foundation.
We remain disciplined in execution and focused on delivering measurable progress for our shareholders.”
Strengthening Long-Term Visibility
With operational platforms now spanning Hangzhou, Nanjing, Qingdao, Wuxi and Wuhu, GV has formed an integrated structure covering strategy, technology, product, and regional sales execution.
This expansion enhances:
• Commercial scalability
• Institutional penetration capability
• Revenue pathway visibility
• Regional diversification
As demand for regenerative medicine and aesthetic treatment continues to expand across Asia, GV believes its structured commercialization approach positions the Company to participate meaningfully in this growth trend.
About Visionary Holdings Inc.
Visionary Holdings Inc. (Nasdaq: GV) is a technology-driven multinational enterprise focused on innovative education, AI applications, and high-tech healthcare solutions. Headquartered in Toronto, Canada, the Company operates through its subsidiaries across North America and Asia, driving technological advancement, cross-border innovation, and global health transformation.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "target," "going forward," "outlook," "objective" and similar terms. Such statements are based upon management's current expectations and current market and operating conditions and relate to events that involve known or unknown risks and uncertainties that may cause actual results to differ materially. Further information regarding these and other risks is included in the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov. The Company undertakes no obligation to update any forward-looking statements except as required by law.
Visionary Holdings Inc.
For further information:
Investor Relations
Visionary Holdings Inc.
Email: ir@visionary.holdings
FAQ**
How does the establishment of new subsidiaries in Qingdao, Wuxi, and Wuhu by Goldfield Corporation (The) GV improve their competitive position in the regenerative medicine and aesthetic treatment markets?
Can Goldfield Corporation (The) GV share specifics on the strategic partnerships formed with regional medical providers and how these will impact sales execution in the new subsidiaries?
What measures is Goldfield Corporation (The) GV implementing to ensure revenue visibility and operational transparency in their newly established centers compared to previous operational models?
How does Goldfield Corporation (The) GV plan to leverage AI-assisted aging assessment systems in their localized sales strategies across the newly formed subsidiaries?
**MWN-AI FAQ is based on asking OpenAI questions about Goldfield Corporation (The) (NASDAQ: GV).
NASDAQ: GV
GV Trading
-12.17% G/L:
$0.628 Last:
252,987 Volume:
$0.7146 Open:
